U.S., Oct. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07894874) titled 'A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.' on Oct. 19.
Brief Summary: This study is a open-label, multicenter clinical trials. The target population is participants with locally advanced or metastatic solid tumors. A total of 204 participants are planned to be included.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumor (Phase I)
Ovarian Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)
TNBC - Triple-Negative Breast Cancer
Intervention:
DRUG: YF550
YF550 will be administered orally once daily in 21-day cycles,Treatment continues until disease progr...